Goldman Sachs Group, Inc. (The) reissued their buy rating on shares of AbbVie Inc. (NYSE:ABBV) in a report released on Friday morning. The firm currently has a $100.00 price target on the stock, up from their prior price target of $85.00.

A number of other research analysts have also recently issued reports on ABBV. BidaskClub raised shares of AbbVie from a buy rating to a strong-buy rating in a research note on Wednesday, September 6th. Credit Suisse Group reissued a neutral rating and issued a $74.00 price objective (up from $65.00) on shares of AbbVie in a research note on Thursday, July 20th. BMO Capital Markets reissued a market perform rating and issued a $66.00 price objective on shares of AbbVie in a research note on Wednesday, May 17th. Leerink Swann reissued a market perform rating on shares of AbbVie in a research note on Thursday, June 22nd. Finally, Vetr cut shares of AbbVie from a buy rating to a hold rating and set a $76.28 price objective on the stock. in a research note on Thursday, July 20th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and an average price target of $79.25.

Shares of AbbVie (ABBV) opened at 87.00 on Friday. The company has a market capitalization of $138.69 billion, a price-to-earnings ratio of 21.40 and a beta of 1.48. AbbVie has a 1-year low of $55.06 and a 1-year high of $87.10. The stock has a 50 day moving average price of $72.68 and a 200 day moving average price of $68.66.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.02. AbbVie had a net margin of 24.77% and a return on equity of 150.27%. The company had revenue of $6.94 billion during the quarter, compared to the consensus estimate of $6.93 billion. During the same period in the previous year, the business earned $1.26 earnings per share. The firm’s quarterly revenue was up 7.6% on a year-over-year basis. Analysts forecast that AbbVie will post $5.52 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “AbbVie Inc. (ABBV) Earns Buy Rating from Goldman Sachs Group, Inc. (The)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/12/abbvie-inc-abbv-earns-buy-rating-from-goldman-sachs-group-inc-the.html.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be paid a dividend of $0.64 per share. The ex-dividend date is Thursday, October 12th. This represents a $2.56 dividend on an annualized basis and a dividend yield of 2.94%. AbbVie’s payout ratio is presently 62.90%.

In related news, Chairman Richard A. Gonzalez sold 87,899 shares of the business’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $71.02, for a total value of $6,242,586.98. Following the sale, the chairman now owns 342,353 shares of the company’s stock, valued at $24,313,910.06. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Chairman Richard A. Gonzalez sold 193,131 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $71.00, for a total transaction of $13,712,301.00. Following the completion of the sale, the chairman now directly owns 469,623 shares in the company, valued at approximately $33,343,233. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 490,491 shares of company stock worth $34,684,639. Insiders own 0.23% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. Formidable Asset Management LLC grew its stake in shares of AbbVie by 0.3% in the second quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock worth $285,000 after purchasing an additional 10 shares during the last quarter. WealthTrust Axiom LLC grew its stake in shares of AbbVie by 0.3% in the second quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock worth $312,000 after purchasing an additional 15 shares during the last quarter. Abner Herrman & Brock LLC grew its stake in shares of AbbVie by 0.3% in the second quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock worth $456,000 after purchasing an additional 18 shares during the last quarter. Bollard Group LLC grew its stake in shares of AbbVie by 0.5% in the second quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock worth $273,000 after purchasing an additional 19 shares during the last quarter. Finally, St. Louis Trust Co grew its stake in shares of AbbVie by 0.7% in the second quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock worth $248,000 after purchasing an additional 23 shares during the last quarter. 68.29% of the stock is currently owned by institutional investors.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.